Rekvina Labs

Why is Rekvina Labs Ltd falling/rising?

As of 03-Aug, Rekvina Labs Ltd's stock price is at 25.00, unchanged from the previous session, and has underperformed its sector by 0.43%. The stock has seen a 1.19% decline over the past week, with decreasing investor participation and inconsistent trading contributing to a negative outlook.

As of 03-Aug, Rekvina Labs Ltd's stock price is currently at 25.00, with no change from the previous trading session. The stock has underperformed its sector by 0.43% today, indicating a decline in relative performance. Over the past week, the stock has decreased by 1.19%, while the benchmark Sensex has increased by 2.35%, further highlighting the stock's weakness compared to the market.<BR><BR>Additionally, there has been erratic trading, as the stock did not trade on 2 out of the last 20 days. This inconsistency may contribute to investor uncertainty. The moving averages show that while the stock is higher than the 200-day moving average, it is lower than the 5-day, 20-day, 50-day, and 100-day moving averages, suggesting a short-term downward trend.<BR><BR>Investor participation is also declining, with a delivery volume of 1.28k on July 31, which has fallen by 10.32% against the 5-day average delivery volume. This drop in participation can indicate a lack of confidence among investors, which may lead to further downward pressure on the stock price. Overall, these factors suggest that Rekvina Labs Ltd is currently experiencing a decline in its stock price.

Which are the latest news on Rekvina Labs?

When is the next results date for Rekvina Labs Ltd?

The next results date for Rekvina Labs Ltd is 13 August 2026.

The next results date for Rekvina Labs Ltd is scheduled for 13 August 2026.

Who are in the management team of Rekvina Labs?

The management team of Rekvina Labs consists of Amit Shah (Director), Mukesh Shah (Director), Vibha Mukesh Shah (Additional Director), and Mahendra Shantilal Dalal (Additional Director).

The management team of Rekvina Labs includes the following individuals:<BR><BR>1. Amit Shah - Director<BR>2. Mukesh Shah - Director<BR>3. Vibha Mukesh Shah - Additional Director<BR>4. Mahendra Shantilal Dalal - Additional Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

Who are the peers of the Rekvina Labs?

Rekvina Labs' peers include Sun Pharma, Divi's Lab, Torrent Pharma, Cipla, Dr Reddy's Labs, Lupin, Cresanto Global, Sang Froid Labs, and Vardhaman Labs. Sun Pharma and Lupin show excellent growth and management quality, while Torrent Pharma has the highest 1-year return at 42.88%, and Cipla has the lowest at -8.95%.

Peers: The peers of Rekvina Labs are Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, Dr Reddy's Labs, Lupin, Cresanto Global, Sang Froid Labs, and Vardhaman Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, Dr Reddy's Labs, and Lupin, while the rest do not qualify. Growth is excellent at Sun Pharma.Inds. and Lupin, good at Dr Reddy's Labs, average at Torrent Pharma, and below average at Divi's Lab. and Cipla, while the rest do not qualify. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, good at Torrent Pharma and Lupin, while the rest do not qualify.<BR><BR>Return Snapshot: Torrent Pharma has the highest 1-year return at 42.88%, while Cipla has the lowest at -8.95%, and Rekvina Labs does not have a 1-year return to compare. Additionally, Cipla and Dr Reddy's Labs have negative six-month returns.

What does Rekvina Labs do?

Rekvina Labs Ltd is an integrated Indian pharmaceutical company specializing in pharmaceutical formulations and contract research and manufacturing services, with a market cap of INR 24 Cr and reported net sales of 1 Cr for the quarter ending March 2026. The company has been operational since 1988 and has evolved significantly in the pharmaceutical industry.

Overview:<BR>Rekvina Labs Ltd is an integrated Indian pharmaceutical company operating in the Micro Cap category, specializing in the production of pharmaceutical formulations and providing contract research and manufacturing services.<BR><BR>History:<BR>Incorporated on 1st November 1988, Rekvina Labs has evolved from a small domestic company in the mid-1980s to a significant player in the pharmaceutical industry, with reported sales exceeding Rs 20 Crore. The latest quarterly results indicate net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 24 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.22<BR>- Return on Equity: 25.00%<BR>- Price to Book: -24.48<BR><BR>Contact Details:<BR>Address: 328 Paradise Complex, Sayajigunj Vadodara Gujarat : 390005 <BR>Tel: 91-265-2362966 <BR>Email: rekvina@gmail.com <BR>Website: http://www.rekvinalaboratories.com

Are Rekvina Labs Ltd latest results good or bad?

Rekvina Labs Ltd's latest results show mixed performance, with a 105.71% revenue increase and a 50% reduction in net loss, but ongoing challenges like negative book value and persistent losses raise concerns about its financial stability and profitability. Overall, the outlook remains cautious despite some positive metrics.

Rekvina Labs Ltd's latest results present a mixed picture. On one hand, there has been a notable improvement in certain metrics; for instance, the company reported a revenue of ₹0.72 crores in Q4 FY26, which is a significant sequential growth of 105.71% compared to the previous quarter. Additionally, the net loss has improved by 50% quarter-over-quarter, now standing at ₹0.06 crores. The operating margin has also shown improvement, moving from -34.29% to -8.33%.<BR><BR>However, despite these positive changes, the company continues to face significant challenges. It has a negative book value, meaning its liabilities exceed its assets, which raises serious concerns about its financial health. The persistent net losses and lack of a clear path to profitability indicate ongoing operational difficulties. Moreover, the stock has experienced considerable volatility and has declined significantly over the past month, reflecting growing investor skepticism.<BR><BR>Overall, while there are signs of improvement in revenue and loss reduction, the fundamental issues regarding profitability and financial stability remain a concern, leading to a cautious outlook on the company's performance.

Should I buy, sell or hold Rekvina Labs Ltd?